LILRB4 play crucial roles in affecting the clinical outcomes of early‐stage PDAC through JAK‐STAT signalling pathway, immune‐related signalling pathways, and tumour‐infiltrating immune cells. This evidence concerns the gene LILRB4 and neoplasm.